ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA
17 oct. 2023 04h00 HE
|
AKAMPION
- Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors ...
Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial
26 sept. 2023 04h00 HE
|
AKAMPION
- MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression- First data readout expected in Q1/ 2024 with study completion planned...
Cellbox Solutions Submits Device Master File (DMF) to the U.S. FDA
25 sept. 2023 04h00 HE
|
AKAMPION
Submission represents an important step towards establishing the Cellbox Live Shipment Technology as a new standard for warm chain logistic in the cell therapy sectorCellbox customers can now...
1ST Biotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate FB849 in Combination With KEYTRUDA® (pembrolizumab)
19 sept. 2023 04h00 HE
|
AKAMPION
YONGIN, South Korea, September 19, 2023 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative...
ImmunOs Therapeutics Appoints Dr. Constanze Guenther as Senior Vice President, CMC and Technical Development
19 sept. 2023 04h00 HE
|
AKAMPION
- Former Novartis Executive Director brings significant expertise in manufacturing, operations, and technical development Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA –...
Thermosome Establishes High-Profile Clinical Advisory Board
19 sept. 2023 04h00 HE
|
AKAMPION
Leveraging the transformative potential of TSL-based tumor targeting Supporting the progress of Thermosome's clinical candidate THE001 Munich, Germany – September 19, 2023 – Thermosome, a drug...
BellaSeno Reports Positive One-Year Patient Follow-Up Data for Resorbable Breast and Pectus Excavatum Scaffolds
05 sept. 2023 04h00 HE
|
AKAMPION
Key milestone for novel, resorbable breast / pectus reconstruction implants Leipzig, Germany, September 5, 2023 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable...
BellaSeno Granted Market Access in Europe for Custom-Made Bone and Pectus Excavatum Scaffolds
06 juil. 2023 04h00 HE
|
AKAMPION
Market entry under new EU regulations for medical devicesSpearheading the commercialization of 3D-printed regenerative medicine products Leipzig, Germany, July 6, 2023 – BellaSeno GmbH, an ISO...
TolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing
06 juil. 2023 04h00 HE
|
AKAMPION
Ongoing Phase IIb study expands to arm B5-year results of phase I study confirm efficacy and safety of novel immune-tolerance inducing cell therapy in organ transplantationSecond closing of Series A...
Cellbox Solutions GmbH Awarded €2.5 Million Grant Combined with an Equity Component of up to €10 Million Under the European Innovation Council´s Accelerator Program
05 juil. 2023 04h00 HE
|
AKAMPION
- Cellbox Solutions selected by the EIC following the second 2023 EIC Accelerator cut-off PRESS RELEASE. Cologne, Germany — July 05, 2023 - Cellbox Solutions GmbH, a leading provider of warm...